{"slideshow_credits": null, "snippet": "A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed.", "abstract": "Institute for Clinical and Economic Review finds cholesterol-lowering drugs Repatha and Praluent are very overpriced given value they offer; report, which is used by health plans in price negotiations, could force drug makers Amgen and Sanofi to offer larger discounts.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/09/09/business/new-cholesterol-drugs-are-vastly-overpriced-analysis-says.html", "lead_paragraph": "A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed.", "headline": {"main": "New Cholesterol Drugs Are Vastly Overpriced, Analysis Says", "print_headline": "New Cholesterol Drugs Are Overpriced, Analysis Finds"}, "_id": "55ef520d38f0d867b4c896af", "word_count": "825", "multimedia": [{"height": 126, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-09-09T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Institute for Clinical and Economic Review", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Cholesterol", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Amgen Inc", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "Sanofi SA", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Health Insurance and Managed Care", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Praluent (Drug)", "is_major": "N", "rank": "8"}, {"name": "subject", "value": "Repatha (Drug)", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}